Condition: Hematological Diseases · Sponsor: Rigshospitalet, Denmark
A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase.
This description comes directly from the study's public registry record.
Mette Schaufuss Engedal, MSc · +45 51896699 · mette.schaufuss.engedal@regionh.dk
Mary Jarden · +4535454368 · mary.jarden@regionh.dk
Always discuss trial participation with your own doctor first.
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06281496